Samlyn Capital »

Enliven Therapeutics shares owned by Samlyn Capital

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Samlyn Capital from 13F filings

Historical chart of Samlyn Capital investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Samlyn Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Samlyn Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $46M 913k 50.75

More positions owned by Samlyn Capital

Lpl Financial Holdings (LPLA)
Primo Brands Corporation Class A Com Shs (PRMB)
First Solar (FSLR)
Taiwan Semiconductor Manufac Sponsored Ads (TSM)
Blackrock (BLK)
Liberty Media Corp Del Com Lbty One S C (FWONK)
Meta Platforms Cl A (META)
JPMorgan Chase & Co. (JPM)
Morgan Stanley Com New (MS)
VSE Corporation (VSEC)
Bank of America Corporation (BAC)
Madison Square Grdn Sprt Cor Cl A (MSGS)
Willscot Hldgs Corp Com Cl A (WSC)
Kaspi Kz Jsc Sponsored Ads (KSPI)
BorgWarner (BWA)

View all positions for Samlyn Capital

Top funds holding Enliven Therapeutics

FMR
OrbiMed Advisors
Polar Capital Holdings
BlackRock
Vestal Point Capital
Commodore Capital
Vanguard Capital Management
Citadel Advisors
Fairmount Funds Management
Siren
Bellevue Group
Geode Capital Management
First Light Asset Management
Pictet Asset Management Holding SA
State Street Corporation

View all funds holding Enliven Therapeutics